News: Becoming pregnant after taking Ocs

Article

Most women who take an OC for at least 1 year resume their regular menses or are able to become pregnant within 90 days of cessation.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Subscribe Now!
Recent Videos
Haluk Damgacioglu, PhD, discusses cervical cancer's link to anal cancer risk | Image Credit: cadsci.com.
Natalia Llarena, MD, discusses rising fertility anxiety in Gen Z | Image Credit: havingbabies.com.
Uma Mahadevan, MD, highlights new guidelines for managing IBD | Image Credit: ucsfhealth.org.
Related Content
Umbilical cord acidemia linked to long-term neurodevelopmental risks | Image Credit: © natali_mis - © natali_mis - stock.adobe.com.

Umbilical cord acidemia linked to long-term neurodevelopmental risks

Contemporary OB/GYN Staff
September 17th 2025
Article

Read More

Pap Talk S4E15: MIRA surgical system for hysterectomy with Jean Dubuisson, MD, PhD

Pap Talk S4E15: MIRA surgical system for hysterectomy with Jean Dubuisson, MD, PhD

Celeste Krewson, Assistant Editor
September 17th 2025
Podcast

Listen

Oral HRT linked to increased heart risks in T2D patients | Image Credit: © Krakenimages.com - © Krakenimages.com - stock.adobe.com.

Oral HRT linked to increased heart risks in T2D patients

Celeste Krewson, Assistant Editor
September 17th 2025
Article

Read More

Site Logo

How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care

September 17th 2025
Podcast

Listen

Molecule shows promise for MASH, endometriosis, and other chronic diseases | Image Credit: © krissikunterbunt - © krissikunterbunt - stock.adobe.com.

Molecule shows promise for MASH, endometriosis, and other chronic diseases

Isabella Backman;Yale School of Medicine - Obstetrics, Gynecology & Reproductive Sciences
September 17th 2025
Article

Read More

Romosozumab outperforms teriparatide and denosumab in bone strength | Image Credit: © RFBSIP - © RFBSIP - stock.adobe.com.

Romosozumab outperforms teriparatide and denosumab in bone strength

Koji Ishikawa, MD, PhD;Tony M. Keaveny, PhD
September 17th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.